Literature DB >> 16773369

[Treatment options for bipolar mania].

T Attarbaschi1, S Kasper.   

Abstract

The diagnosis and treatment of bipolar mania are extremely challenging. Therapeutic intervention for mania has traditionally relied on the use of lithium or divalproex as a first-line treatment option. However, due to the limited therapeutic range of these agents, typical neuroleptics have often been used. Although these have demonstrated efficacy in mania, they are often associated with significant side effects, especially extrapyramidal symptoms. Thus, atypical antipsychotics are increasingly preferred in the treatment of bipolar mania. In this review, data from controlled studies for several of the atypical antipsychotics in the treatment of mania are surveyed and issues in the selection of an appropriate atypical agent are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773369     DOI: 10.1007/s00115-006-2096-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  49 in total

Review 1.  Selection of initial treatment for bipolar disorder, manic phase.

Authors:  M A Frye; L L Altshuler
Journal:  Mod Probl Pharmacopsychiatry       Date:  1997

2.  Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.

Authors:  Sumant Khanna; Eduard Vieta; Benjamin Lyons; Fred Grossman; Mariëlle Eerdekens; Michelle Kramer
Journal:  Br J Psychiatry       Date:  2005-09       Impact factor: 9.319

3.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

4.  Prevalence of overweight and obesity in bipolar patients.

Authors:  J L Elmslie; J T Silverstone; J I Mann; S M Williams; S E Romans
Journal:  J Clin Psychiatry       Date:  2000-03       Impact factor: 4.384

5.  Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

Authors:  Mauricio Tohen; K N Roy Chengappa; Trisha Suppes; Carlos A Zarate; Joseph R Calabrese; Charles L Bowden; Gary S Sachs; David J Kupfer; Robert W Baker; Richard C Risser; Elisabeth L Keeter; Peter D Feldman; Gary D Tollefson; Alan Breier
Journal:  Arch Gen Psychiatry       Date:  2002-01

Review 6.  Atypical antipsychotics in mood disorders.

Authors:  Siegfried Kasper; Mara Stamenkovic; Martin Letmaier; Daniel Schreinzer
Journal:  Int Clin Psychopharmacol       Date:  2002-08       Impact factor: 1.659

7.  Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.

Authors:  G Sachs; K N R Chengappa; T Suppes; J A Mullen; M Brecher; N A Devine; D E Sweitzer
Journal:  Bipolar Disord       Date:  2004-06       Impact factor: 6.744

8.  Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

9.  Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.

Authors:  Gary S Sachs; Fred Grossman; S Nassir Ghaemi; Akiko Okamoto; Charles L Bowden
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 10.  Issues in the treatment of bipolar disorder.

Authors:  Siegfried Kasper
Journal:  Eur Neuropsychopharmacol       Date:  2003-08       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.